Banner for leaf pages 2


Also known as Samsca

Tolvaptan (INN), also known as OPC-41061, is a selective, competitive vasopressin receptor 2 antagonist used to treat hyponatremia (low blood sodium levels) associated with congestive heart failure, cirrhosis, and the syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan was approved by the U.S. Food and Drug Administration (FDA) on May 19, 2009, and is sold by Otsuka Pharmaceutical Co. under the trade name Samsca and in India is manufactured & sold by MSN laboratories Ltd. under the trade name Tolvat & Tolsama.

Source: Wikipedia

Estimated Total Cost: $5511.04 for an average of 21 days supply

What is it prescribed for?

Patients are most commonly prescribed tolvaptan to treat rabies, blastomycosis, west nile virus, and pick disease.

What side effects are related?

Patients taking tolvaptan most commonly experience side effects like mouth dryness, frequent urination, and polyuria.

Ajax-loader Loading...